Title: 
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Senate Study Bill 1138 - Introduced SENATE FILE _____ BY (PROPOSED COMMITTEE ON HEALTH AND HUMAN SERVICES BILL BY CHAIRPERSON KLIMESH) A BILL FOR An Act relating to a review of anti-obesity medications by the 1 department of health and human services and the department 2 of administrative services for purposes of the medical 3 assistance program and health insurance plans for public 4 employees. 5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 6 TLSB 1939XC (3) 91 lh/ko S.F. _____ Section 1. ANTI-OBESITY MEDICATION REVIEW AND REPORT. For 1 purposes of the medical assistance program under chapter 2 249A and health insurance plans established pursuant to 3 chapter 509A for public employees, the department of health 4 and human services and the department of administrative 5 services shall review anti-obesity medications, including 6 GLP-1 agonists, for effectiveness relating to weight loss, 7 the impact on comorbidities, the potential for cost savings 8 due to deferred medical procedures and reduced medications 9 related to comorbidity, recommended eligibility requirements, 10 and any other criteria the departments deem relevant. The 11 department of health and human services and the department of 12 administrative services shall submit a report to the general 13 assembly by January 5, 2026, with the departmentsâ findings and 14 proposed eligibility requirements. 15 EXPLANATION 16 The inclusion of this explanation does not constitute agreement with 17 the explanationâs substance by the members of the general assembly. 18 This bill relates to the department of health and human 19 services (HHS) and the department of administrative services 20 (DAS) review of anti-obesity medication for purposes of 21 the medical assistance program and health insurance plans 22 established pursuant to Code chapter 509A for public employees. 23 The bill requires HHS and DAS to review anti-obesity 24 medications, including GLP-1 agonists, for effectiveness, 25 comorbidities, cost savings, and eligibility requirements as 26 described in the bill. HHS and DAS shall submit a report to the 27 general assembly by January 5, 2026, containing HHSâs and DASâs 28 findings and proposed eligibility requirements. 29 -1- LSB 1939XC (3) 91 lh/ko 1/ 1


================================================================================

Raw Text:
Senate Study Bill 1138 - Introduced SENATE FILE _____ BY (PROPOSED COMMITTEE ON HEALTH AND HUMAN SERVICES BILL BY CHAIRPERSON KLIMESH) A BILL FOR An Act relating to a review of anti-obesity medications by the 1 department of health and human services and the department 2 of administrative services for purposes of the medical 3 assistance program and health insurance plans for public 4 employees. 5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA: 6 TLSB 1939XC (3) 91 lh/ko S.F. _____ Section 1. ANTI-OBESITY MEDICATION REVIEW AND REPORT. For 1 purposes of the medical assistance program under chapter 2 249A and health insurance plans established pursuant to 3 chapter 509A for public employees, the department of health 4 and human services and the department of administrative 5 services shall review anti-obesity medications, including 6 GLP-1 agonists, for effectiveness relating to weight loss, 7 the impact on comorbidities, the potential for cost savings 8 due to deferred medical procedures and reduced medications 9 related to comorbidity, recommended eligibility requirements, 10 and any other criteria the departments deem relevant. The 11 department of health and human services and the department of 12 administrative services shall submit a report to the general 13 assembly by January 5, 2026, with the departmentsâ findings and 14 proposed eligibility requirements. 15 EXPLANATION 16 The inclusion of this explanation does not constitute agreement with 17 the explanationâs substance by the members of the general assembly. 18 This bill relates to the department of health and human 19 services (HHS) and the department of administrative services 20 (DAS) review of anti-obesity medication for purposes of 21 the medical assistance program and health insurance plans 22 established pursuant to Code chapter 509A for public employees. 23 The bill requires HHS and DAS to review anti-obesity 24 medications, including GLP-1 agonists, for effectiveness, 25 comorbidities, cost savings, and eligibility requirements as 26 described in the bill. HHS and DAS shall submit a report to the 27 general assembly by January 5, 2026, containing HHSâs and DASâs 28 findings and proposed eligibility requirements. 29 -1- LSB 1939XC (3) 91 lh/ko 1/ 1